1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus molecular subtypes (CMS). However, the impact of inter-cellular interaction between these cellular states on the emergence of drug resistance and CRC progression remains elusive. Here, we explored the interaction between cell lines belonging to the CMS1 (HCT116 and LoVo) and the CMS4 (SW620 and MDST8) in a 3D coculture model, mimicking the ITH of CRC. The spatial distribution of each cell population showed that CMS1 cells had a preference to grow in the center of cocultured spheroids, while CMS4 cells localized at the periphery, in line with observations in tumors from CRC patients. Cocultures of CMS1 and CMS4 cells did not alter cell growth, but significantly sustained the survival of both CMS1 and CMS4 cells in response to the front-line chemotherapeutic agent 5-fluorouracil (5-FU). Mechanistically, the secretome of CMS1 cells exhibited a remarkable protective effect for CMS4 cells against 5-FU treatment, while promoting cellular invasion. Secreted metabolites may be responsible for these effects, as demonstrated by the existence of 5-FU induced metabolomic shifts, as well as by the experimental transfer of the metabolome between CMS1 and CMS4 cells. Overall, our results suggest that the interplay between CMS1 and CMS4 cells stimulates CRC progression and reduces the efficacy of chemotherapy.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

          In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Consensus Molecular Subtypes of Colorectal Cancer

            Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression–based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMS) with distinguishing features: CMS1 (MSI Immune, 14%), hypermutated, microsatellite unstable, strong immune activation; CMS2 (Canonical, 37%), epithelial, chromosomally unstable, marked WNT and MYC signaling activation; CMS3 (Metabolic, 13%), epithelial, evident metabolic dysregulation; and CMS4 (Mesenchymal, 23%), prominent transforming growth factor β activation, stromal invasion, and angiogenesis. Samples with mixed features (13%) possibly represent a transition phenotype or intra-tumoral heterogeneity. We consider the CMS groups the most robust classification system currently available for CRC – with clear biological interpretability – and the basis for future clinical stratification and subtype–based targeted interventions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Microenvironmental regulation of metastasis.

              Metastasis is a multistage process that requires cancer cells to escape from the primary tumour, survive in the circulation, seed at distant sites and grow. Each of these processes involves rate-limiting steps that are influenced by non-malignant cells of the tumour microenvironment. Many of these cells are derived from the bone marrow, particularly the myeloid lineage, and are recruited by cancer cells to enhance their survival, growth, invasion and dissemination. This Review describes experimental data demonstrating the role of the microenvironment in metastasis, identifies areas for future research and suggests possible new therapeutic avenues.
                Bookmark

                Author and article information

                Contributors
                valerie.taly@parisdescartes.fr
                wenjin.xiao@sorbonne-universite.fr
                Journal
                Cell Death Dis
                Cell Death Dis
                Cell Death & Disease
                Nature Publishing Group UK (London )
                2041-4889
                5 May 2023
                5 May 2023
                May 2023
                : 14
                : 5
                : 306
                Affiliations
                [1 ]GRID grid.4444.0, ISNI 0000 0001 2112 9282, Centre de Recherche des Cordeliers, INSERM, CNRS, , Université Paris Cité, Sorbonne Université, USPC, Equipe labellisée Ligue Nationale contre le cancer, ; Paris, France
                [2 ]GRID grid.7429.8, ISNI 0000000121866389, Platform for Metabolic Analyses, , Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS 3633, ; Paris, France
                [3 ]GRID grid.417925.c, Equipe labellisée par La Ligue contre le cancer, , Université Paris Cité, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, ; Paris, France
                [4 ]GRID grid.14925.3b, ISNI 0000 0001 2284 9388, Metabolomics and Cell Biology Platforms, , Gustave Roussy Cancer Center, ; Villejuif, France
                [5 ]GRID grid.414093.b, ISNI 0000 0001 2183 5849, Institut du Cancer Paris CARPEM, Department of Biology, , Hôpital Européen Georges Pompidou, AP-HP, ; Paris, France
                [6 ]GRID grid.414093.b, ISNI 0000 0001 2183 5849, Institut du Cancer Paris CARPEM, Department of Oncology, , Hôpital Européen Georges Pompidou, AP-HP, ; Paris, France
                Author information
                http://orcid.org/0000-0002-3931-7414
                http://orcid.org/0000-0001-8080-839X
                http://orcid.org/0000-0002-6081-9558
                http://orcid.org/0000-0002-9334-4405
                http://orcid.org/0000-0002-8950-1949
                http://orcid.org/0000-0001-8475-5459
                http://orcid.org/0000-0001-5891-142X
                Article
                5806
                10.1038/s41419-023-05806-z
                10160076
                37142595
                e2469d6c-5b80-43eb-8881-5bba3a5721e2
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 11 October 2022
                : 3 April 2023
                : 11 April 2023
                Funding
                Funded by: SIRIC Cancer Research and Personalized Medicine (CARPEM) Alliance Nationale pour les Sciences de la Vie et de la Santé
                Funded by: FundRef https://doi.org/10.13039/100010665, EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions);
                Award ID: 813786
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100001665, Agence Nationale de la Recherche (French National Research Agency);
                Award ID: ANR-17-EURE-0013
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100006537, Campus France (Agence Française pour la Promotion de l'Enseignement Supérieur, l'Accueil et la Mobilité Internationale);
                Categories
                Article
                Custom metadata
                © Associazione Differenziamento e Morte Cellulare ADMC 2023

                Cell biology
                tumour heterogeneity,cancer models
                Cell biology
                tumour heterogeneity, cancer models

                Comments

                Comment on this article